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restabilization of IkBa after NF-kB activa-
tion, apparently through recruiting the
protein to the CSN-associated deubiqui-
tylating enzyme USP15. Whether this
mechanism is also at play in CSN-medi-
ated Snail stabilization remains to be
investigated (Figure 1). Likewise, future
work will be required to clarify the role, if
any, of CSN-mediated cullin deneddyla-
tion in Snail stabilization. For example,
one wonders whether the Snail stabilizing
activity of CSN5 depends on the integrity
of its JAMM metalloprotease domain.
The finding that CAND1 is required for
CSN2-induced Snail accumulation is
intriguing in this regard, but difficult to
reconcile with other reports demon-
strating that, in vivo, CAND1 behaves as
an activator of CRLs (Zheng et al., 2002),
although this has not been established
forSCFb-TRCP. Basedon thedata available
to date, it appears that preventing Snail
phosphorylation is the primary role of the
CSN in Snail stabilization.
Regardless of the exact mechanism,
the current study deepens the link
between inflammation and metastasis
and introduces theCSNas a further player
in these processes. The new findings
also provide initial mechanistic insight
into the emerging connection between
CSN activation and tumorigenesis (Adler
et al., 2008).
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Transitions between epithelial and mesenchmal phenotypes play critical roles in normal development and
cancer progression. In this issue of Cancer Cell, Evdokimova et al. demonstrate that YB-1 regulates epi-
thelial-mesenchyme transition (EMT) by inducing cap-independent translation of mRNAs encoding EMT-
promoting factors and suppressing cap-dependent translation of mRNAs encoding growth-promoting
factors.Metastasis is a multistep process that
mediates the spread of cancer cells from
primary tumors to distant sites. This
process relies on structural and pheno-
typic changes that enable tumor cells to
dissociate from the tumor mass, invade
the surrounding tissue, intravasate into
vascular or lymphatic vessels, and extrav-
asate and proliferate at a secondary site.
An increasing number of reports provide
evidence that epithelial cancer cells adopt
embryonic transcription programs during
the invasive phase of metastasis, which
allow them to suspend some or all of theirepithelial properties and acquire those
of mesenchymal cells (Thiery and Slee-
man, 2006; Yilmaz and Christofori, 2009).
This epithelial-to-mesenchymal transition
(EMT) is associated with changes in cell-
cell adhesion, remodeling of cell-matrix
adhesion, and enhanced migratory ac-
tivity. Several transcription factors have
been implicated in this transition, including
Snail, Slug, Zeb1, andTwist. The canonical
Ras pathway has also been shown to play
a crucial role in EMT in certain contexts.
Ras activity, however, is not sufficient to
induce EMT; other factors collaborateCancer Cwith Ras to orchestrate this process
(Thiery, 2003). The relevance of EMT as
an integral and obligate phase of cancer
cell invasion/metastasis in vivo is contro-
versial; in fact, several cancer cell types
are able to invade by adopting modes of
migration that don’t involve an EMT, such
as collective or amoeboid (Friedl et al.,
2004). Nevertheless, an increasing body
of evidence demonstrates the occurrence
of EMT in tumor cell subpopulationsduring
the progression of certain types of cancers
(Yilmaz and Christofori, 2009; Polyak and
Weinberg, 2009), and a recent studyell 15, May 5, 2009 ª2009 Elsevier Inc. 357
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PreviewsFigure 1. Model for EMT Translational Control by YB-1
EMT in Ras-transformed cells is dependent on two events.
(A) Transcription of genes that induce EMT and promote proliferation.
(B) YB-1 suppression of the translation of proliferation genes (suppression of cap-dependent translation)
and induction of the translation of EMT genes (induction of cap-independent translation).shows that EMT in vivo might be particu-
larly important for a subset of tumors,
especially for those with basal phenotype
(Sarrio et al., 2008).
In this issue of Cancer Cell, Evdoki-
mova, Sorensen, and colleagues identify
YB-1 (Y-box binding protein-1) as a new
player in the regulation of EMT through
a novel mechanism involving translation
of cap-independent mRNAs encoding
Snail and other EMT regulators in Ras-
transformed cells (Evdokimova et al.,
2009). YB-1, a DNA/RNA-binding protein
with a conserved cold-shock domain,
has been implicated in tumor progression;
however, the exact role of YB-1 in this
process is ambiguous since it has been
described as both a tumor suppressor
andanoncogene.YB-1’sactivityasa tran-
scriptional activator in the nucleus has
been reported to be protumorigenic:
YB-1 induces proliferation by activating
progrowth genes through binding to the
Y-box elements in their promoter region
(Evdokimova et al., 2006). In contrast, in
the cytoplasm, YB-1 can silence transla-
tion through binding to the 50 terminus of
mRNAs with extensive 50 UTR secondary
structures, thus outcompeting the eIF4E
initiation complex (Evdokimova et al.,
2006). Many of these YB-1-silenced
mRNAs encode growth-related proteins
and are dependent on 50 cap-binding
proteins for initiation of translation. Hence,
YB-1 can suppress growth and prolifera-
tion and has been described to possess
tumor suppressorproperties (Evdokimova
et al., 2006).358 Cancer Cell 15, May 5, 2009 ª2009 ElseIn this issue’s report, YB-1 is described
as a crucial factor in the initiation of the
translation of a set of cap-independent
mRNA transcripts. Microarray analysis of
translationally active and inactive mRNAs
identified several known EMT-regulatory
factors, including the transcription factors
Snail1 and Twist, that were differentially
translated in Ras-transformed cells. The
authors further demonstrated that YB-1
overexpression could increase Snail1
proteinexpressionand inducesubsequent
EMT. The 50 UTR of Snail1 mRNA is pre-
dicted to form highly stable stem-loop
structures with conserved nucleotides,
resembling the structure of internal ribo-
some entry sites (IRES), which mediate
cap-independent translation initiation
directly activated by YB-1 binding. In
parallel, YB-1 overexpression in Ras-
transformed human breast epithelial cells
suppressed translation of transcripts
involved in cell proliferation and induced
proliferation arrest. Hence, YB-1 plays a
dichotomous role in translational regula-
tion: it suppresses the cap-dependent
translation initiation of progrowth mRNAs
and promotes the cap-independent trans-
lation initiation of EMT-inducing mRNAs,
the transcription of which is induced by
sustained Ras-Erk activation.
Therefore, EMT induction in Ras-trans-
formed cells involves two steps: (1) Ras
induces the transcription of EMT-medi-
ating factors (including Snail 1 and Twist)
and (2) YB-1 induces the translation of
these factors concomitant with the sup-
pression of the expression of growthvier Inc.related transcripts (Figure 1). While the
studies in this report involved analysis of
tumor cells expressing an H-Ras onco-
gene, it is predicted that YB-1 could
collaborate with other genes that promote
transcription of EMT-regulatory mRNAs.
These studies highlight the critical role
of YB-1 in the coordinated induction of
both EMT and proliferation arrest. Inter-
estingly, an invasion ‘‘signature,’’ derived
by analysis of mRNAs from invading cells
associated with mouse and rat tumors,
exhibited an increase in the expression
levels of genes that induce migration and
suppress proliferation and apoptosis and
a decrease in the expression levels of
genes that promote proliferation (Condee-
lis et al., 2005); this change ingeneexpres-
sion is consistent with a coordination of
invasive behavior and proliferation arrest.
The dormancy of invading cells, more-
over, could contribute to the failure of
most tumor cells to expand at secondary
sites. YB-1 expression could arrest
proliferation of metastatic cells through
silencing of translation of mRNAs required
for proliferation. If such a mechanism
takes place, release from dormancy may
involve inactivation of YB-1 translational
regulation. Akt phosphorylation of YB-1
has been shown to inhibit YB-1 binding
to the 50UTR cap (Evdokimova et al.,
2006). Thus, this phosphorylation event
is predicted to promote proliferation by
releasing the YB-1 imposed block on the
translation of growth-regulatory genes.
Interestingly, it has been suggested that
the escape from dormancy at metastatic
sites is contingent on the reversal of EMT
in a mesenchymal-to-epithelial transition
(MET) (Chaffer et al., 2007; Polyak and
Weinberg, 2009).
Another interesting finding in this report
is that YB-1 regulates expression of
several progenitor cell markers (upregula-
tion of p63,CD44, andCD10, anddownre-
gulation of CD24). This is consistent with
recent studies that indicate a link between
EMT and acquisition of stem/progenitor
cell properties (Polyak and Weinberg,
2009). Together, these studies support
the notion that tumor cells undergo dedif-
ferentiation through EMT. During meta-
static progression, this dedifferentiated
mesenchymal state could revert back to
an epithelial state (MET) upon expansion
at secondary tumor sites. According to
this scenario, cancer cells that metasta-
size could be derived from primary site
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Previewsepithelial tumorcells thatunderwenta tran-
sient dedifferentiation associated with
EMT rather than cancer stem cells that
pre-exist asa subpopulationof theprimary
tumor. YB-1 gain or loss of translational
control could potentially be involved in
the regulation of both EMT and MET,
respectively.
Thesestudies raise thequestion: isYB-1
a target for therapeutic intervention in
metastasis? As the authors point out,
direct targeting of YB-1 might prove to be
futile or even counterproductive since
YB-1 could be an important factor inAgonizing Integrin
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A recent study published in Nature
inhibitors may paradoxically enhan
these agents should be redesigned
efficacy to treat human cancers.
Integrins mediate cell-cell and cell-matrix
interactions to ‘‘integrate’’ extracellular
cues with intracellular signaling pathways
and to promote a wide array of biological
responses. During development, tissue
remodeling, and in various disease condi-
tions, integrin-mediated cell migration/
invasion occurs via transient binding and
release of the extracellular matrix (ECM).
Thus, local microenvironments containing
substrate and soluble protein fragments
provide situational cues to integrins which
guide cell behavior. Several integrins,
including avb3 and avb5, recognize the
arginine-glycine-aspartic acid (RGD) se-
quence shared by a number of extra-
cellular matrix ligands. Accordingly, RGD-
mimetic peptides or small molecules bind
to these integrins on the surface of cells to
block specific av integrin-mediated sig-
naling pathways and act as anticancer
and antiangiogenic agents.
Reynolds and colleagues recently re-
ported in Nature Medicine that low nano-
molar concentrations of RGD mimeticskeeping cells dormant after they metasta-
size.
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in order to avoid nanomolar plasma c
may actually stimulate tumor growth and
angiogenesis (Reynolds et al., 2009).
These conclusions were drawn from
examination of B16F0 melanoma or LLC
lung carcinoma cells grown on the flanks
of syngeneic C57BL6 mice treated sys-
temically with a cyclic RGD peptide (cilen-
gitide) or a small molecule RGD mimetic
(S 36578). Since the RGD mimetics did
not increase tumor growth or vasculariza-
tion in integrin b3/b5 double knockout
mice, the authors concluded that low
doses of integrin antagonists promoted
tumor growth by acting on host endothe-
lial cells. While these findings may seem
surprising, several independent groups
reported in the early 1990s that nanomo-
lar concentrations of soluble ECM pro-
teins could induce chemotaxis (Aznavoor-
ian et al., 1990) and that the chemotaxis
induced specifically by RGD-containing
fibronectin fragments could be overcome
by millimolar concentrations of RGD-con-
taining peptides (Odekon et al., 1991). As
a rationale for their experiments, Rey-
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atment with RGD-mimetic integrin
This work implies that delivery of
oncentrations and to improve their
nolds et al. also pointed to work by Legler
and coworkers who found that cyclic
RGD-peptides have a biphasic effect on
avb3, with an antagonistic phase at high
concentrations and an agonistic phase
at low concentrations (Legler et al.,
2001). Thus, it has been known for years
that low concentrations of soluble antag-
onists will agonize or ‘‘superactivate’’
(Legler et al., 2001) integrins (Figure 1).
Nonetheless, in their new study, Reynolds
et al. have extended these previous find-
ings to confirm that integrin activation by
low-dose antagonists does occur in
endothelial cells and may be relevant for
angiogenesis among subcutaneously
growing tumors.
The authors commented in the paper
that integrin antagonism as an antiangio-
genic therapy has been largely unsuc-
cessful in man and that any observed
efficacy is probably due to direct ac-
tion on tumor cells. While it is generally
true that many antiangiogenic strategies
for cancers have performed below
ell 15, May 5, 2009 ª2009 Elsevier Inc. 359
